- Home
- NRIM vs MNPR Comparison
NRIM vs MNPR Comparison
Compare NRIM & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRIM | MNPR |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.4M | 531.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NRIM | MNPR |
|---|---|---|
| Price | $26.95 | $61.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $97.83 |
| AVG Volume (30 Days) | 175.3K | ★ 283.1K |
| Earning Date | 01-23-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ 91.08 | N/A |
| EPS | ★ 2.80 | N/A |
| Revenue | ★ $201,544,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.55 | N/A |
| P/E Ratio | $9.68 | ★ N/A |
| Revenue Growth | ★ 42.34 | N/A |
| 52 Week Low | $16.18 | $22.50 |
| 52 Week High | $28.21 | $105.00 |
Technical Indicators
Market Signals| Indicator | NRIM | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 54.15 | 30.16 |
| Support Level | $26.26 | $63.73 |
| Resistance Level | $27.71 | $70.01 |
| Average True Range (ATR) | 0.66 | 4.83 |
| MACD | -0.08 | -0.68 |
| Stochastic Oscillator | 37.57 | 23.77 |
Price Performance
Historical ComparisonAbout NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.